Antiviral Drug Resistance Market

Description

The market for antiviral drug resistance is anticipated to grow from US$ 3.71 billion in 2024 to US$ 6.35 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.9% during the period from 2031 to 2031. Key trends driving this market include the rising incidence of liver diseases, the ongoing prevalence of HIV and AIDS, and the increasing demand for high-quality products in developing countries.

Analysis of the Antiviral Drug Resistance Market

Globally, the prevalence of HIV/AIDS has seen a significant rise in recent years. Acquired immunodeficiency syndrome (AIDS), a chronic and potentially fatal condition, is caused by the human immunodeficiency virus (HIV), which severely compromises the immune system and hinders the body's ability to combat infections. Following the entry of HIV into the body, individuals may experience flu-like symptoms within a month, known as primary or acute HIV infection, which can last for several weeks. According to the US Department of Health & Human Services and the Secretary's Minority AIDS Initiative Fund (SMAIF), approximately 39 million individuals were living with HIV/AIDS globally in 2022, with a significant proportion residing in low- and middle-income countries. For example, the India HIV Estimation 2017 report (National Informatics Centre) estimates the HIV prevalence in India at 0.22% (ranging from 0.16% to 0.30%). Furthermore, the adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and 0.19% (0.14%-0.25%) among females. Consequently, the rising cases of viral infections in India are expected to boost the demand for antiviral drug resistance solutions during the forecast period.

Overview of the Antiviral Drug Resistance Market

The increasing rates of hepatitis and the growing prevalence of HIV/AIDS are propelling market growth. Additionally, the expansion of emerging markets is likely to positively influence demand during the forecast period. However, market growth may be hindered by alternative treatment approaches. In the United States, the prevalence of HIV has risen in recent years. Data from the US Department of Health & Human Services and the SMAIF indicates that nearly 32,100 Americans were newly diagnosed with HIV in 2021. These factors are expected to drive the growth of the antiviral drug resistance market in North America throughout the forecast period.

Strategic Insights

Drivers and Opportunities in the Antiviral Drug Resistance Market

Increasing Incidence of Hepatic Diseases to Benefit the Market

Viruses, which are microscopic pathogens, can lead to various infectious diseases, including the flu, common cold, and warts, as well as severe conditions like smallpox, HIV/AIDS, and Ebola. They replicate within host cells and can invade any healthy living cells, multiplying and producing more viruses. Different viruses target specific cells in the body, such as those in the liver, brain, skin, blood, and various systems including reproductive, respiratory, and gastrointestinal. The incidence of viral infections, particularly hepatitis, has risen globally in recent years. Hepatitis can cause liver damage and inflammation, posing a significant global health challenge that can lead to chronic infections and increased mortality risk from cirrhosis and liver cancer. Hepatitis is classified into types A, B, C, D, and E, each with different transmission methods. According to the World Health Organization (WHO), the highest prevalence of Hepatitis B is found in the African and Western Pacific regions, with infection rates of 6.1% and 6.2% among the adult populations, respectively.

Rising Healthcare Investments in Emerging Markets

Growing healthcare expenditures in emerging markets, particularly in the Asia Pacific and South and Central America, are facilitating the development of treatment options for various viral diseases through advanced techniques such as PCR (Polymerase Chain Reaction) and next-generation sequencing. Organizations like the National Cancer Institute (NCI) are funding research on HIV and AIDS-related malignancies to understand how aging with chronic HIV infections affects cancer risk, spectrum, and biology. Countries like China, Japan, and Brazil are significantly investing in healthcare to enhance their market presence and ensure the effective use of medical instruments and reagents in hospitals, research institutes, and diagnostic laboratories.

Segmentation Analysis of the Antiviral Drug Resistance Market

The antiviral drug resistance market analysis is segmented by type, disease indication, technology, and end users.

By type, the market is categorized into kits and reagents, and instruments, with kits and reagents holding the largest market share in 2023.
By disease indication, the market is divided into HIV, hepatitis, and Cytomegalovirus (CMV), with the HIV segment commanding the largest share in 2023.
In terms of technology, the market includes immunodiagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, with immunodiagnostics holding a significant market share in 2023.
By end users, the market is segmented into hospitals and clinics, pathology or diagnostic laboratories, and research institutes, with hospitals and clinics representing the largest share in 2023.

Geographical Analysis of the Antiviral Drug Resistance Market

The geographical scope of the antiviral drug resistance market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America holds the largest market share for antiviral drug resistance, driven by factors such as the prevalence of viral infections like HIV and hepatitis, as well as government-funded national programs. The incidence of HIV in the US has risen in recent years, with approximately 32,100 new infections reported in 2021. The Asia Pacific region is expected to experience the highest CAGR in the coming years.

Scope of the Antiviral Drug Resistance Market Report

Recent Developments in the Antiviral Drug Resistance Market

The antiviral drug resistance market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Notable developments in the antiviral drug resistance market include:

Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of new data in the journal Nature, indicating that an early-stage clinical candidate (JNJ-1802) offers strong protection against dengue in non-human primates and mice. This first-in-class antiviral, which was found to be safe and well-tolerated in a Phase 1 clinical study, is advancing to Phase 2 clinical trials for dengue prevention and treatment. (Source: Johnson & Johnson, Press Release, March 2023)
Cipla Limited received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for the launch of Molnupiravir in India, which will be marketed under the brand name Cipmolnu(R). Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating mild-to-moderate COVID-19 in patients at high risk of severe disease. (Source: Cipla, Press Release, May 2021)

Coverage and Deliverables of the Antiviral Drug Resistance Market Report

The report titled "Antiviral Drug Resistance Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

Market size and forecast for antiviral drug resistance at global, regional, and country levels across all key segments.
Market trends and dynamics, including drivers, restraints, and key opportunities.
Detailed PEST/Porter's Five Forces and SWOT analysis.
Market analysis covering key trends, global and regional frameworks, major players, regulations, and recent developments.
Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments in the antiviral drug resistance market.
In-depth company profiles.

Product Code: TIPRE00006395

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Antiviral Drug Resistance Market and By Product
- 1.3.2 Global Antiviral Drug Resistance Market and By Disease Indication
- 1.3.3 Global Antiviral Drug Resistance Market and By Technology
- 1.3.4 Global Antiviral Drug Resistance Market and By End User
- 1.3.5 Global Antiviral Drug Resistance Market and By Geography

2. Global Antiviral Drug Resistance Market and Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Antiviral Drug Resistance Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 Middle East and Africa PEST Analysis
- 4.2.5 South and Central America PEST Analysis
4.3 Expert Opinion
4.4 Cost of Test, By Test Type
4.5 Test Volume, By Region

5. Global Antiviral Drug Resistance Market and Key Industry Dynamics

5.1 Key Market Drivers
- 5.1.1 Rise in the Incidences of Hepatitis Diseases
- 5.1.2 Increasing Prevalence of HIV/AIDS
5.2 Key Market Restraints
- 5.2.1 Alternative Approaches
5.3 Key Market Opportunities
- 5.3.1 Increasing Healthcare Expenditures in Emerging Markets
5.4 Future Trends
- 5.4.1 Demand For Higher Quality Products
5.5 Impact Analysis

6. Antiviral Drug Resistance Market and Global Analysis

6.1 Global Antiviral Drug Resistance Market Revenue Forecasts And Analysis
6.2 Global Antiviral Drug Resistance Market, By Geography - Forecasts And Analysis
6.3 Positioning of Key Players

7. Global Antiviral Drug Resistance Market Analysisand by Product

7.1 Overview
7.2 Global Antiviral Drug Resistance Market Share by Product 2018 and 2031 (%)
7.3 Kits and Reagents
- 7.3.1 Overview
- 7.3.2 Kits and Reagents Market Revenue and Forecast to 2031 (US$ Mn)
7.4 Instruments
- 7.4.1 Overview
- 7.4.2 Instruments Market Revenue and Forecast to 2031 (US$ Mn)

8. Global Antiviral Drug Resistance Market Analysisand by Disease Indication

8.1 Overview
8.2 Global Antiviral Drug Resistance Market Share by Disease Indication 2018 and 2031 (%)
8.3 HIV
- 8.3.1 Overview
- 8.3.2 HIV Market Revenue and Forecast to 2031 (US$ Mn)
8.4 Hepatitis
- 8.4.1 Overview
- 8.4.2 Hepatitis Market Revenue and Forecast to 2031 (US$ Mn)
8.5 Cytomegalovirus (CMV)
- 8.5.1 Overview
- 8.5.2 Cytomegalovirus (CMV) Market Revenue and Forecast to 2031 (US$ Mn)

9. Global Antiviral Drug Resistance Market Analysisand by Technology

9.1 Overview
9.2 Global Antiviral Drug Resistance Market Share by Technology 2018 and 2031 (%)
9.3 Immunodiagnostics
- 9.3.1 Overview
- 9.3.2 Immunodiagnostics Market Revenue and Forecast to 2031 (US$ Mn)
9.4 Polymerase Chain Reaction (PCR)
- 9.4.1 Overview
- 9.4.2 Polymerase Chain Reaction (PCR) Market Revenue and Forecast to 2031 (US$ Mn)
9.5 Next Generation Sequencing (NGS)
- 9.5.1 Overview
- 9.5.2 Next Generation Sequencing (NGS) Market Revenue and Forecast to 2031 (US$ Mn)
9.6 Other Technologies
- 9.6.1 Overview
- 9.6.2 Other Technologies Market Revenue and Forecast to 2031 (US$ Mn)

10. Global Antiviral Drug Resistance Market Analysisand by End User

10.1 Overview
10.2 Global Antiviral Drug Resistance Market Share by End User 2018 and 2031 (%)
10.3 Hospitals and Clinics
- 10.3.1 Overview
- 10.3.2 Hospitals And Clinics Market Revenue and Forecast to 2031 (US$ Mn)
10.4 Pathology and Diagnostic Laboratories
- 10.4.1 Overview
- 10.4.2 Pathology and Diagnostic Laboratories Market Revenue and Forecast to 2031 (US$ Mn)
- 10.4.3 List of Laboratories, By Region
10.5 Research Institutes
- 10.5.1 Overview
- 10.5.2 Research Institutes Market Revenue and Forecast to 2031 (US$ Mn)

11. Antiviral Drug Resistance Market Revenue and Forecasts to 2031 and Geographical Analysis

11.1 North America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
- 11.1.1 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
- 11.1.2 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
- 11.1.3 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
- 11.1.4 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
- 11.1.5 North America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.1.6 North America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
- 11.1.7 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.7.1 US Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.7.2 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.1.7.3 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.1.7.4 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.1.7.5 US Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.1.8 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.8.1 Canada Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.8.2 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.1.8.3 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.1.8.4 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.1.8.5 Canada Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.1.9 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.9.1 Mexico Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.1.9.2 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.1.9.3 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.1.9.4 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.1.9.5 Mexico Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
11.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts To 2031
- 11.2.1 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
- 11.2.2 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
- 11.2.3 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
- 11.2.4 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
- 11.2.5 Europe Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.2.6 Europe Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
- 11.2.7 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.7.1 UK Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.7.2 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.2.7.3 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.2.7.4 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.2.7.5 UK Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.2.8 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.8.1 Germany Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.8.2 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.2.8.3 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.2.8.4 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.2.8.5 Germany Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.2.9 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.9.1 France Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.9.2 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.2.9.3 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.2.9.4 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.2.9.5 France Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.2.10 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.10.1 Italy Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.10.2 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.2.10.3 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.2.10.4 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.2.10.5 Italy Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.2.11 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.11.1 Spain Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.2.11.2 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.2.11.3 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.2.11.4 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.2.11.5 Spain Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
11.3 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031
- 11.3.1 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
- 11.3.2 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
- 11.3.3 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
- 11.3.4 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
- 11.3.5 Asia Pacific Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.3.6 Asia Pacific Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
- 11.3.7 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.7.1 Japan Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.7.2 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.3.7.3 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.3.7.4 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.3.7.5 Japan Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.3.8 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.8.1 China Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.8.2 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.3.8.3 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.3.8.4 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.3.8.5 China Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.3.9 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.9.1 India Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.9.2 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.3.9.3 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.3.9.4 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.3.9.5 India Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.3.10 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.10.1 South Korea Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.10.2 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.3.10.3 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.3.10.4 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.3.10.5 South Korea Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.3.11 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.11.1 Australia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.3.11.2 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.3.11.3 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.3.11.4 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.3.11.5 Australia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
11.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts To 2031
- 11.4.1 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
- 11.4.2 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
- 11.4.3 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
- 11.4.4 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
- 11.4.5 Middle East and Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.4.6 Middle East and Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
- 11.4.7 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.7.1 UAE Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.7.2 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.4.7.3 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.4.7.4 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.4.7.5 UAE Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.4.8 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.8.1 Saudi Arabia Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.8.2 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.4.8.3 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.4.8.4 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.4.8.5 Saudi Arabia Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.4.9 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.9.1 South Africa Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.4.9.2 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.4.9.3 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.4.9.4 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.4.9.5 South Africa Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
11.5 South And Central America Antiviral Drug Resistance Market Revenue And Forecasts To 2031
- 11.5.1 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
- 11.5.2 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
- 11.5.3 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
- 11.5.4 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
- 11.5.5 South and Central America Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.5.6 South and Central America Antiviral Drug Resistance Market Revenue and Forecasts to 2031, By Country (%)
- 11.5.7 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.5.7.1 Argentina Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.5.7.2 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.5.7.3 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.5.7.4 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.5.7.5 Argentina Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)
- 11.5.8 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.5.8.1 Brazil Antiviral Drug Resistance Market Revenue and Forecasts to 2031 (US$ Mn)
  - 11.5.8.2 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Product (US$ Mn)
  - 11.5.8.3 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Disease Indication (US$ Mn)
  - 11.5.8.4 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By Technology (US$ Mn)
  - 11.5.8.5 Brazil Antiviral Drug Resistance Market Revenue And Forecasts to 2031, By End User (US$ Mn)

12. Antiviral Drug Resistance Marketand Industry Landscape

12.1 Overview

13. Antiviral Drug Resistance MarketandKey Company Profiles

13.1 AccuBioTech Co., Ltd.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Financial Overview
- 13.1.4 Product Portfolio
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 ACON Laboratories, Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Financial Overview
- 13.2.4 Product Portfolio
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Siemens AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Financial Overview
- 13.3.4 Product Portfolio
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 bioMerieux SA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Financial Information
- 13.4.4 Product Portfolio
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Bio-Rad Laboratories, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Financial Information
- 13.5.4 Product Portfolio
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Danaher
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Financial Overview
- 13.6.4 Product Portfolio
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Abbott
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Financial Overview
- 13.7.4 Product Portfolio
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 BD
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Financial Overview
- 13.8.4 Product Portfolio
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Financial Overview
- 13.9.4 Product Portfolio
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Trinity Biotech
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Financial Overview
- 13.10.4 Product Portfolio
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms